<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850873</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3616-I-0001</org_study_id>
    <nct_id>NCT03850873</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics</brief_title>
  <official_title>A Phase I Clinical， Tolerance and Pharmacokinetic Evaluation of 1 Schedules of Oral TQB3616，A Cyclin-Dependent Kinase Inhibitor ，In Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TQB3616 may work in cancer by stopping cancer cells from multiplying.TQB3616 is in a new
      class of drugs called CDK inhibitors.This research study is the first time that TQB3616 will
      be given to people.TQB3616 is taken by mouth daily.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>Dose-Limiting Toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>Maximum Tolerated Dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0(pre-dose),1,2,4,6,8,12,24,36,48,72,120,168hours post-dose on single dose ; Hour 0(pre-dose) of day1,day7,day14,day21,day28 on multiple dose and Hour 0(pre-dose),1,2,4,6,8,12,24hours post-dose on multiple dose of day28</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hour 0(pre-dose),1,2,4,6,8,12,24,36,48,72,120,168hours post-dose on single dose ; Hour 0(pre-dose) of day1,day7,day14,day21,day28 on multiple dose and Hour 0(pre-dose),1,2,4,6,8,12,24hours post-dose on multiple dose of day28</time_frame>
    <description>Maximum Observed Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Hour 0(pre-dose),1,2,4,6,8,12,24,36,48,72,120,168hours post-dose on single dose ; Hour 0(pre-dose) of day1,day7,day14,day21,day28 on multiple dose and Hour 0(pre-dose),1,2,4,6,8,12,24hours post-dose on multiple dose of day28</time_frame>
    <description>Terminal Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Hour 0(pre-dose),1,2,4,6,8,12,24,36,48,72,120,168hours post-dose on single dose ; Hour 0(pre-dose) of day1,day7,day14,day21,day28 on multiple dose and Hour 0(pre-dose),1,2,4,6,8,12,24hours post-dose on multiple dose of day28</time_frame>
    <description>Area Under the Curve</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TQB3616</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m to 120mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3616</intervention_name>
    <description>TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily</description>
    <arm_group_label>TQB3616</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years old

          2. Patients definitely diagnosed by pathology and/or cytology as advanced breast cancer
             with ER+、Her2-,who failed with standard endocrine therapy.

          3. ECOG PS:0-1,Survival is expected to be greater than 3 months

          4. Main organs function is normal or must meet the following criteria(within past 14
             days) 1) hemoglobin≥90g/L; neutrophils≥1.5 x109/L; Platelets≥100 x109/L
             2)Albumin≥29g/L; total bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic
             transaminase(AST) and alanine transaminase(ALT)≤2.5 ULN, and ≤ 5 x ULN with hepatic
             metastasis;serum creatinine ≤1.5 xULN，creatinine clearance &gt;60ml/min;
             Triglyceride≤3.0mmol/L, cholesterol≤7.75mmol/L

        3)Doppler ultrasound evaluation: Left ventricular ejection fraction(LVEF)≥50% 5.Patients
        should be voluntary and sign the informed consent before taking part in the study

        Exclusion Criteria:

          1. Patients with malignant tumors, except for Cured cutaneous basal cell carcinoma and
             cervical carcinoma in situ

          2. Prior treatment with chemotherapy with cytotoxic drugs within 4 weeks, mitomycin C or
             nirtosocarbamide within 8 weeks

          3. Prior treatment with any anti-cancer therapy including hormone therapy
             radioimmunotherapy, molecular targeted therapy, immunotherapy or other biological
             therapy with 2 weeks

          4. Patients treated with other CDK4/6 inhibitors;

          5. Patients with brain metastasis, spinal cord compression, cancerous meningitis, CT or
             MRI examination reminds patients with cerebral or soft meningeal diseases in the
             screening phase;

          6. Previous history of stem cell or bowe marrow transplant;

          7. A variety of factors that affect oral medication (such as inability to swallow,
             gastrointestinal resection, intestinal obstruction, etc.)

          8. Patients with non-healing wounds or fractures, except for bone metastatics with
             pathologic frature

          9. Previous history of uncontrolled cardiovascular disease including: a) Grade 3 or
             higher congestive heart failure (NYHA Classification);b)unstable angina pectoris or
             newly developped angina pectoris within 3months before the trial; c) Myocardial in
             farction or stroke occured within 6 months prior to intiation of trial; d) Arrhythmias
             requiring antiarrhythmic treatment(beta-blocker or digoxin is permitted)

         10. Patients who need to take CYP3A4 inhibitors or inducers from the screening period;

         11. Patients with drug abuse history or unable to get rid of drugs or Patients with mental
             disorders

         12. Patients with the urine protein≥2+, total ammount of 24 hours urinary protein
             determination＞1.0 grams;

         13. Patients with hyperactive/venous thrombosis events within 6 months,such as
             cerebrovascular accidents (including temporary ischemic attack), deep venous
             thrombosis and pulmonary embolism

         14. Patients with active hepatitis b or c infection

         15. Patients with immunodeficiency, including HIV positive or other acquired, congenital
             immunodeficiency disease, or organ transplant history;

         16. Patients allergic to TQB3616 or any adjuvant in the capsule

         17. Patients who took part in other trials within 4 weeks;

         18. Patients with concomitant diseases which could seriously endanger themselves or those
             who won't complete the study according to investigators;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ZeFei Jiang, Doctor</last_name>
    <phone>010-66947171</phone>
    <email>jiangzefei@csco.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongmei Yin, Doctor</last_name>
  </overall_contact_backup>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

